<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04277429</url>
  </required_header>
  <id_info>
    <org_study_id>THERESE</org_study_id>
    <nct_id>NCT04277429</nct_id>
  </id_info>
  <brief_title>HFpEF and 2-year Mortality of COPD Patients</brief_title>
  <acronym>THERESE</acronym>
  <official_title>The Influence of hearT Failure With Preserved Ejection Fraction on 2year Mortality of Patients With cHronic obstructivE pulmonaRy disEaSE- THERESE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Olomouc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Olomouc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to assess potential relationship between heart failure with preserved&#xD;
      ejection fraction and 2- year mortality of patients with chronic obstructive pulmonary&#xD;
      disease&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>2 year</time_frame>
    <description>Mortality of patients</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Normal cardiac function</arm_group_label>
    <description>Normal cardiac function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heart failure with reduced ejection fraction</arm_group_label>
    <description>Heart failure with reduced ejection fraction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heart failure with preserved ejection fraction</arm_group_label>
    <description>Heart failure with preserved ejection fraction</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac function assessment</intervention_name>
    <description>Echocardiography, cardiac enzymes analysis</description>
    <arm_group_label>Heart failure with preserved ejection fraction</arm_group_label>
    <arm_group_label>Heart failure with reduced ejection fraction</arm_group_label>
    <arm_group_label>Normal cardiac function</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic obstructive pulmonary disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Exacerbation of chronic obstructive pulmonary disease requiring hospitalization&#xD;
&#xD;
        Age 40 - 80 years&#xD;
&#xD;
        Performance status 0-1 according to Eastern Cooperative Oncology Group (ECOG)&#xD;
&#xD;
        Long acting beta agonist (LABA)/ long acting antimuscarinic (LAMA) bronchodilator treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Presence of major heart valve dysfunction&#xD;
&#xD;
        Documented noncompliance with treatment&#xD;
&#xD;
        Presence of active malignancy&#xD;
&#xD;
        Body mass index &gt; 40&#xD;
&#xD;
        Interstitial lung disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milan Sova, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Respiratory Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Milan Sova, Ph.D.</last_name>
    <phone>588445326</phone>
    <email>milan.sova@email.cz</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ondrej Zela, MD</last_name>
    <email>ondrej.zela@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Frydek Mistek Hospital</name>
      <address>
        <city>Frýdek-Místek</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ondrej Zela</last_name>
      <email>zela@nemfm.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Olomou</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milan Sova</last_name>
      <phone>588445326</phone>
      <email>milan.sova@fnol.cz</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 17, 2020</study_first_submitted>
  <study_first_submitted_qc>February 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Olomouc</investigator_affiliation>
    <investigator_full_name>Milan Sova</investigator_full_name>
    <investigator_title>Principal Investigator, Department of Respiratory Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

